(ANSA) - ROME, DEC 30 - Published in the Official Gazette the AIFA determines the methods of use and the conditions of administration of the Merck anti-viral pill for the treatment of Covid "in adult patients not hospitalized for Covid 19 with disease mild-moderate of recent onset and with concomitant clinical conditions that represent specific risk factors ". "The prescription and treatment - reads the determination - must guarantee the administration of the product as early as possible with respect to the onset of symptoms and in any case no later than 5 days from the beginning of the same".
The selection of the patient, as indicated by the AIFA - is entrusted to general practitioners, doctors of the Usca and in general to doctors who "have the opportunity to come into contact with patients suffering from recent onset Covid and with mild to moderate symptoms and to quickly direct them to the facility where the prescription is to be made and to the distribution of the drug and must take place in compliance with the criteria set by the CTS ". Again according to the indications of the drug agency, the Merck pill can be prescribed only to "doctors working in the structures identified by the regions for administration".The definition of the path through which the patients eligible for treatment are identified - concludes the AIFA document - is left to the provisions of the Regions and autonomous provinces ". (ANSA).